<DOC>
	<DOCNO>NCT01533740</DOCNO>
	<brief_summary>Aim present study investigate whether baseline early post-treatment ( one month treatment commencement ) frequency peripheral T regulatory lymphocyte ( Tregs OR CD4+/CD25high/FOXP3+ T cell ) , know suppress antitumor immune response , may influence long-term clinical outcome ( i.e . radiological response , progression-free survival overall survival ) metastatic colorectal cancer patient treated standard first-line chemotherapy include fluorouracil , irinotecan bevacizumab</brief_summary>
	<brief_title>Circulating Regulatory Lymphocytes Outcome Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>patient histologically cytologically confirm diagnosis metastatic colorectal cancer amenable surgery Adjuvant treatment end ≥6 month study entry No prior exposure irinotecan and/or bevacizumab adjuvant treatment No prior exposure cytotoxic drug metastatic disease At least one measurable lesion accord RECIST criterion adequate laboratory parameter ( Hemoglobin level ≥ 9.0 g/dL ; Neutrophil count &gt; 1.5 x 109/L ; Platelets count &gt; 100 x 109/L ; Total bilirubin &lt; 1.5 time uppernormal limit ( UNL ) ASAT ( SGOT ) and/or ALAT ( SGPT ) &lt; 2.5 x UNL , &lt; 5 x UNL case liver metastasis ; alkaline phosphatase &lt; 2.5 x UNL , &lt; 5 x UNL case liver metastasis ; PTINR/PTT &lt; 1.5 x UNL ; Creatinine clearance &gt; 50 mL/min serum creatinine &lt; 1.5 x UNL ; Urine dipstick proteinuria &lt; 2+ ) Written informed consent . Patients must accessible treatment follow . Untreated brain metastasis spinal cord compression History inflammatory bowel disease and/or acute subacute bowel occlusion . Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy . Uncontrolled hypertension . Clinically significant cardiovascular disease ( cerebrovascular accident ≤ 6 month , myocardial infarction ≤ 6 month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication ) Current recent ( within 10 day prior study treatment start ) ongoing treatment anticoagulant therapeutic purpose . Chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) medication know predispose gastrointestinal ulceration . Treatment investigational drug within 30 day prior enrolment . Patients know allergy Chinese hamster ovary cell protein , component study medication Other coexist malignancy malignancy diagnose within last 5 year exception basal squamous cell carcinoma cervical cancer situ Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study . Pregnant lactate woman . Women childbearing potential either positive pregnancy test baseline Substance abuse , medical , psychological social condition may interfere participation study evaluation study result Patients unable swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>